Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis[1].
Molecular Weight:
(144.31 kDa)
Purity:
99.91
CAS Number:
[2283348-97-8]
Target:
Apoptosis
Application Notes:
Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
